EC Number |
Substrates |
Organism |
Products |
Reversibility |
---|
1.14.15.6 | (20R,22R)-20,22-dihydroxy-cholesterol + 2 reduced adrenodoxin + O2 |
- |
Rattus norvegicus |
pregnenolone + 4-methylpentanal + 2 oxidized adrenodoxin + 2 H2O |
- |
? |
1.14.15.6 | (20R,22R)-20,22-dihydroxy-cholesterol + 2 reduced adrenodoxin + O2 |
- |
Homo sapiens |
pregnenolone + 4-methylpentanal + 2 oxidized adrenodoxin + 2 H2O |
- |
? |
1.14.15.6 | (20R,22R)-20,22-dihydroxy-cholesterol + 2 reduced adrenodoxin + O2 |
- |
Bos taurus |
pregnenolone + 4-methylpentanal + 2 oxidized adrenodoxin + 2 H2O |
- |
? |
1.14.15.6 | (20R,22R)-20,22-dihydroxy-cholesterol + 2 reduced adrenodoxin + O2 |
- |
Rattus norvegicus Wistar |
pregnenolone + 4-methylpentanal + 2 oxidized adrenodoxin + 2 H2O |
- |
? |
1.14.15.6 | (20S)-22-thiacholesterol + reduced adrenodoxin + O2 |
- |
Bos taurus |
(20S,22R)-22-thiacholesterol S-oxide + (20S,22S)-22-thiacholesterol S-oxide |
(22R)-sulfoxide preferentially formed by a factor of 4.2 to 1 over (22S)-sulfoxide |
? |
1.14.15.6 | (22R)-22-hydroxycholesterol + 2 reduced adrenodoxin + O2 |
- |
Rattus norvegicus |
(20R,22R)-20,22-dihydroxycholesterol + 2 oxidized adrenodoxin + H2O |
- |
? |
1.14.15.6 | (22R)-22-hydroxycholesterol + 2 reduced adrenodoxin + O2 |
- |
Homo sapiens |
(20R,22R)-20,22-dihydroxycholesterol + 2 oxidized adrenodoxin + H2O |
- |
? |
1.14.15.6 | (22R)-22-hydroxycholesterol + 2 reduced adrenodoxin + O2 |
- |
Bos taurus |
(20R,22R)-20,22-dihydroxycholesterol + 2 oxidized adrenodoxin + H2O |
- |
? |
1.14.15.6 | (22R)-22-hydroxycholesterol + 2 reduced adrenodoxin + O2 |
product binding structure analysis, detailed overview |
Bos taurus |
(20R,22R)-20,22-dihydroxycholesterol + 2 oxidized adrenodoxin + H2O |
- |
? |
1.14.15.6 | (22R)-22-hydroxycholesterol + 2 reduced adrenodoxin + O2 |
- |
Rattus norvegicus Wistar |
(20R,22R)-20,22-dihydroxycholesterol + 2 oxidized adrenodoxin + H2O |
- |
? |